Clinical trials: Liver Biomarkers
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Liver transplantation is a lifesaving procedure; however, there are chances that the body may reject the organ following liver transplantation, and this remains a significant concern.
- Trial name
- NCT06153641
- Testing
- N/A-Observational Study
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
alpha1 Anti-trypsin, Pre-Eclampsia
Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women
Intrauterine growth restriction (IUGR) is defined as a velocity of fetal growth less than the normal fetus growth potential for a specific neonate as per the race and gender.
- Conditions
- alpha1 Anti-trypsin, Pre-Eclampsia, Intrauterine Growth Restriction
- Trial name
- NCT05622838
- Testing
- Alpha1 -Antitrypsin level
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients
This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included…
- Trial name
- NCT03250572
- Testing
- serum ferritin
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma, Liver Cirrhosis
The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma
The aim of this work is to study the role of long non-coding RNAs WRAP53 and urothelial carcinoma-associated 1 (UCA1) as potential biomarkers in diagnosis of hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Diagnoses Disease
- Trial name
- NCT05088811
- Testing
- WRAP53, UCA-1
- Where
- 2 sites in Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease
Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)
This single-center, prospective, observational, cross-sectional mechanistic pilot study will evaluate whether polycystic ovary syndrome (PCOS) contributes to hepatic steatosis in adolescent girls independently of adiposity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Hyperandrogenism
- Trial name
- COMPASSpedPCOS (NCT07731373)
- Testing
- Extended Serum Biomarker and Hormonal Panel, Liver Elastography with Controlled Attenuation Parameter, Targeted Genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kayseri City Hospital
Obesity, Childhood, NAFLD
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process.
- Trial name
- NCT06229184
- Testing
- Fecal Calprotectin Test
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Hepatocellular Carcinoma, Hepatitis B
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI
Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin(DCP) are used as the tumor markers for diagnosis of HCCs.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
- Trial name
- NCT00154531
- Where
- Taiwan
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Non-Alcoholic Fatty Liver Disease, Obesity
Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver
The objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (Study I: case-control study), and 2) to develop a…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- MicroKid (NCT04575506)
- Testing
- Multidisciplinary intervention program
- Where
- 2 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
NAFLD, NASH
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
This study will validate recently developed Magnetic Resonance Imaging (MRI) and Ultrasound (US) based methods for liver fat quantification in children with obesity and healthy range of body mass index (BMI).
- Trial name
- NCT06354491
- Testing
- Magnetic Resonance Imaging (MRI), Ultrasound (US)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital